为了正常的体验网站,请在浏览器设置里面开启Javascript功能!
首页 > 溶酶体贮积病_英文_

溶酶体贮积病_英文_

2011-07-04 3页 pdf 203KB 42阅读

用户头像

is_055297

暂无简介

举报
溶酶体贮积病_英文_ ·综述 · L ysosoma l storage d isorders Yong QU△ (Department of Genetic Testing, Kaiser Permanente, Southern California, 4580 Electronics Place, Los Angeles, CA 90039, USA) SUMM ARY  Lysosomal storage disorders (LSD s) are genetic defects caused by lysosomal hydrol...
溶酶体贮积病_英文_
·综述 · L ysosoma l storage d isorders Yong QU△ (Department of Genetic Testing, Kaiser Permanente, Southern California, 4580 Electronics Place, Los Angeles, CA 90039, USA) SUMM ARY  Lysosomal storage disorders (LSD s) are genetic defects caused by lysosomal hydrolase deficiencies. These deficiencies lead to substrate accumulation affecting cells, tissues and organs. Detecting abnormal compound excretion and deficient enzymes assist diagnosis of these disorders for treatment and p revention. This m ini review summarizes clinical p resentations and diagnostic workup of LSD s and updates the new development in the area. KEY WO RD S   Lysosomal storage diseases; Mucopolysaccharidoses; O ligosaccharidoses; Mucolip idoses; Sphingolip ido2 ses   Lysosomes are single membrane2bound organelles containing many hydrolytic enzymes involved in the degradation of a variety of biologicalmacromolecules. If one ormore enzyme is deficient, the accumulation of these molecules is inevitable. Lysosomal storage disorders (LSD s) rep resent a group of over 45 distinct genetic diseases and are characterized by intracellular accumula2 tion of these compounds. U sually, babies with LSD s are born normal. W hen the harmful molecules build up to a certain threshold, patients start to show symp tom s, such as coarsening of the facial features, organomegaly, dysostosismultip lex and losing developmental m ilestones. Then, the patients will deteriorate with retarded growth and development. Unrelenting p rogression p roceeds, sometimes, slowly, but steadily. LSD s can be divided into several categories according to the compounds stored in the body, such as, mucopolysaccharidoses (MPS) , oligosaccharidoses (OS) , mucolip idoses (ML ) , and sphingolip idoses. This m ini review will use one or two examp les in each of these categories to illustrate clinical symp tom s, en2 zymes deficient in disorders and diagnostic p rocedures. O ther ly2 sosomal disorders, such as Pompe disease, lip id storage diseases and lysosomal transport defects will not be discussed here. 1 M ucopolysacchar idoses(M PS) MPS are p rototypes of LSD s due to storage of glycosam ino2 glycans ( GAG). GAG molecules are long, unbranched polysac2 charide chains, made up of repeating disaccharide units rich in sulfate group s. They are found in connective tissue, cartilage and the nervous system. There are six major types of MPS[ 1, 2 ]. A ll are inherited in an autosomal recessive pattern excep t type Ⅱ, Hunter disease, which is X2linked. Patients with MPS usually show symp tom s beyond six months of age. There is a broad spectrum of clinical p resenta2 tion, usually with coarse facial features, corneal clouding, dys2 ostosis multip lex, short stature, kyphosis, stiff joints, hepato2 sp lenomegaly, cardiac comp lications, and mental retardation. These patients excrete large amounts of abnormal mucopolysac2 charides: dermatan, heparan and keratan sulfates, which can be detected using thin2layer chromatography ( TLC) and /or electro2 phoresis. D iagnostic work2up usually starts with a urine screen2 ing assay followed by enzyme confirmation test using p lasma, leukocytes or fibroblasts. DNA mutation analysis can be done on the diagnosed patients to p rovide a reliable way for p renatal diag2 nosis in future p regnancies and fam ily carrier studies as needed. MPS type Ⅰ, Hurler disease ( including Scheie and Hurl2 er/Scheie) , is caused by deficiency ofα2iduronidase. MPS Ⅱ, Hunter disease, is the result of iduronate sulfatase deficiency. Patients with Hurler or Hunter diseases excrete dermatan and heparan sulfates that can be detected by an MPS urine screening test. Sanfilippo patients (MPS Ⅲ) may have one of the four en2 zyme deficiencies: heparan N 2sulfatase, α2N 2acetylglucosam ini2 dase, acetyl2CoA: α2glucosam inide2N2acetyl transferase, and N2 acetyl2α2D2glucosam inide262sulfatase. Insufficient activity from these enzymes can lead to Sanfilippo type A, B, C, and D, re2 spectively. These patients excrete heparan sulfate in abnormally large amounts. Patients with MPS Ⅳ, Morquio syndrome, lack one of the enzymes, galactose262sulfatase (Morquio A) orβ2gal2 actosidase (Morquio B). They only excrete keratan sulfate as the abnormal compound. Maroteaux2Lamy disease, type Ⅵ, is caused by deficient arylsulfatase B activity and can be screened by finding dermatan sulfate excretion. Sly disease, type Ⅶ, shows variable patterns of mucopolysaccharide excretion on a TLC p late. Plasmaβ2glucuronidase is a reliable test to identify Sly patients. Case 1: An eighteen2month2old boy was seen due to severe infection. On the MR I, cerebral atrophy was observed. On the physical exam, the patient had coarse facial features, lip s thick2 ened with a large tongue and hirsute. A urine screening test for LSD s revealed highly increased excretions of dermatan and hepa2 ran sulfates. Lysosomal enzyme tests on the leukocytes showed almost undetectable iduronate sulfatase activity. The patient was diagnosed with Hunter disease. Case 2: A four2year2old boy was seen in a metabolic clinic for a mental retardation work2up. The patient developed normally at first. By age one, he had frequent infections with slower de2 velopment. A t age two, the boy started hyperactivity with aggres2 sive behavior. On the physical exam ination, he had coarse hair, m ild hepatosp lenomegaly with delayed speech development, p ro2 gressive dementia with cortical atrophy visible on CT scanning. U rine screening tests showed a heavy band of heparan sulfate. Enzyme studies in fibroblasts confirmed that he had Sanfilippo type A with heparan N2sulfatase deficiency. 2 O ligosacchar idoses ( O S) and m ucolip idoses(ML ) OS and ML may also be called glycop roteinoses. Enzymes removing oligosaccharides from glycop rotein are deficient in OS so that glycop rotein cannot be comp letely degraded. In ML, N2 acetylglucosam ine212phosphotransferase is reduced or absent, causing multip le enzyme accumulation in extracellular space with a reduction inside the lysosomes. Glycop roteinoses, in general, clinically resemble the muco2 polysaccharidoses, with coarse facial features, skeletal deform i2 ties, p rogressive neurological degeneration and mental impair2 ment, seizures, visceral involvement; some may have angiokera2 toma, cherry2red retinal spots, and hearing loss. However, MPS tests are often negative for these patients. Thin2layer chromato2 graphy can detect abnormal urinary excretion of oligosaccharides and free sialic acid. The definitive diagnosis should be confirmed by enzyme study in p lasma, leukocytes or fibroblasts. OS include the following disorders (with deficient enzyme in parenthesis) :α2mannosidosis (α2mannosidase ) ,β2mannosido △Corresponding author’s e2mail, yongqu4580@ yahoo. com ·001· 北 京 大 学 学 报 ( 医 学 版 ) JOURNAL OF PEKING UN IVERSITY(HEALTH SC IENCES)  Vol. 38 No. 1 Feb. 2006 sis (β2mannosidase) , α2fucosidosis (α2fucosidase) , sialidosis (α2neuram inidase, also called ML Ⅰ) , galactosialidosis (p ro2 tective p rotein ) , aspartylglucosam inuria ( aspartylglucosam ini2 dase) , and Schindler disease (α2N2acetylgalactosam inidase). A ll are inherited in an autosomal recessive pattern. Traditionally, the term mucolip idosis type Ⅰ is also used for sialidosis. ML Ⅱ ( also called I2cell disease) and ML Ⅲ ( also called p seudo2Hurler polydystrophy) are associated with the deficiency of the same enzyme, N2acetylglucosam ine212phos2 photransferase, which is involved in post2translational modifica2 tion of lysosomal enzymes. W ithout this modification, the phos2 phomannosyl recognition marker will be absent. Therefore, mul2 tip le lysosomal enzymes will not be targeted into lysosomes for p roper function. A s a result, there will be reduced activities of multip le enzymes inside cells. These enzymes will accumulate in the extracellular space resulting in highly elevated p lasma en2 zyme levels. ML Ⅱ is more severe with early onset. ML Ⅲ is m ilder with later onset, p robably due to retained residue enzyme activities. Case: An 112month2old girl, born with swollen gum, was e2 valuated for very advanced dysostosis multip lex. By 11 months, she had slightly coarse facial features with p sychomotor retarda2 tion and m ild hepatosp lenomegaly. A lysosomal urine screening test showed two abnormal bands on oligosaccharide TLC p late with highly elevated p lasma β2glucuronidase activity. Further confirmative tests revealed highly elevated p lasma activity and re2 duced leukocyte activity of multip le lysosomal enzymes, reaching a diagnosis ofML Ⅱ. 3 Sph ingolip idoses Sphingolip ids are comp lex membrane lip idswhich are deriv2 atives of ceram ide ( composed of a C218 am ino alcohol sphingo2 sine and a long2chain fatty acid ) with various polar head group s[ 3 ]. They can be classified into three main categories: cer2 ebrosides (with single sugar) , sphingomyelins (with phosphoryl2 choline or phosphorylethanolam ine) and gangliosides (with sev2 eral sugar units containing sialic acid residues). Sphingolip ido2 ses are disorders in the catabolism of sphingolip ids due to defi2 ciencies of lysosomal hydrolases breaking down these comp lex membrane lip ids. Sphingolip ids are found mainly in the brain and other nerve tissues. Therefore, sphingolip idoses usually p resent with p rimary disturbances in the nervous system, such as p rogressive p sycho2 motor retardation, seizures, spasticity, irritability, some with leukodystrophy, cherry2red macula spots, angiokeratoma, hepa2 tosp lenomegaly, and foam cells in the bone marrow. Most diag2 noses are based on clinical manifestation and enzyme studies. Some of these disorders may be detected by oligosaccharide anal2 ysis using TLC technique. Patients with these disorders usually have negative MPS test results. Sphingolip idoses include the following disorders (with defi2 cient enzyme in parenthesis) : N iemann2Pick disease A and B ( sphingomyelinase ) , Gaucher disease ( glucocerebrosidase ) , Fabry disease ( ceram ide trihexosidase) , Farber disease ( ceram2 idase) , GM1 gangliosidosis (β2galactosidase) , GM2 gangliosido2 sis (β2hexosam inidase A and B) , metachromatic leukodystrophy ( arylsulfatase A) and Krabbe disease (β2galactocerebrosidase). A ll are autosomal recessive disorders excep t Fabry disease, which is X2linked. Case: A 162month2old boy was seen in a genetic clinic for losing m ilestones. The patient was able to babble at 6 months of age, sit up at 10 months, and reach and grasp objects at 12 months. By 14 months, the boy could no longer sit2up; at 15 months, no more roll over. He could not hold an object by 16 months of age. On the physical exam, there were no dysmorphic features, no organomegaly, and no cherry2red spots. The urine oligosaccharide analysis revealed four abnormal bands. Lysosom2 al enzyme studies p roved that the patient hadβ2galactosidase de2 ficiency and both parents are obligate carriers with 50% of the enzyme activity. GM1 gangliosidosis was the diagnosis. 4 New developm en t Traditionally, the treatment of LSD s focuses on managing the symp tom s of the diseases, such as painkilling drugs, cardiac intervention, and kidney dialysis if needed. For the past decade, two new developments in LSD s have emerged and lead to imp res2 sive p rogress. One is treatment; and the other, newborn screen2 ing [ 4 ] . Before 1991, bone marrow and organ transp lantations were attemp ted in treating LSD s. The results varied due to donor vari2 ations and the high mortality risk of the p rocedure. If the engraft2 ment was successful, leukocyte enzyme activity normalized, and organomegaly decreased, but skeletal abnormalities and brain function remained largely unchanged. Some patients continued to deteriorate[ 5 ]. In 1991, enzyme rep lacement therapy was used for the first time to treat one specific disease, such as alglucerase for Gaucher disease type Ⅰ, which is particularly common a2 mong A shkenazi Jews. After enzyme rep lacement therapy, many Gaucher patients have experienced decreasing organ size (within 6 months) , dim inishing bone pains with imp roved growth and development. Due to remarkable success of this treatment, to2 day, some patients with Fabry and Hurler (MPS Ⅰ) diseases are also undergoing enzyme rep lacement therapy[ 6 ]. The results are very p rom ising. The availability of new treatments stimulates interest in new2 born screening for lysosomal storage disorders, since many chil2 dren with LSD s could benefit from early diagnosis and interven2 tion. Now, two techniques are available for newborn screening of some LSD s[ 7, 8 ]. In a recent paper, W ang et al[ 9 ] described the method of measuring at least six lysosomal enzyme activities on a single p latform, suitable for newborn screening. The fast p ro2 gress in the research for diagnosing and treating LSD s is bringing hope to patients with these disorders and their fam ilies. References [ 1 ] Neufeld EF, Muenzer J. The mucopolysaccharidoses[M ] / /Scriver CR, Beaudet AL, Valle D, SlyW S. The metabolic and molecular bases of inherited disease, 8 th ed. New York:McGraw2H ill, 2001: 3421 - 34521 [ 2 ] Nyhan WL, Ozand PT. A tlas of metabolic diseases [ M ]. New York: Chapman & HallMedical, 1998: 440 - 486. [ 3 ] Barth PG. Sphingolip ids[M ] / / Fernandes J, Saudubray JM, Van den Berghe G. Inborn metabolic diseases: diagnosis and treatment, 2nd ed. Berlin: Sp ringer2Verlag, 1995: 375 - 382. [ 4 ] M illington DS. Newborn screening for lysosomal storage disorders [ J ]. Clin Chem, 2005, 51: 808 - 809. [ 5 ] KrivitW , Shap iro EG. Bone marrow transp lantation for storage dis2 eases [ M ] / /Desnick RJ. Treatment of genetic diseases. New York: Churchill L ivingstone, 1991: 203 - 222. [ 6 ] Desnick RJ. Enzyme rep lacement and enhancement therap ies for ly2 sosomal diseases[ J ]. J InheritMetab D is, 2004, 27: 385 - 410. [ 7 ] Chamoles NA, B lanco M, Gaggioli D. D iagnosis of a2L2iduronidase deficiency in dried bloodspots on filter paper: the possibility of newborn diagnosis[ J ]. Clin Chem, 2001, 47: 780 - 781. [ 8 ] Gerber SA, Scott CR, Turecek F, et al. D irect p rofiling of multi2 p le enzyme activities in human cell lysates by affinity chromatogra2 phy/ electrosp ray ionization mass spectrometry: app lication to clini2 cal enzymology[ J ]. Anal Chem, 2001, 73: 1651 - 1657. [ 9 ] W ang D, Eadala B, Sadilek M, et al. Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns[ J ]. Clin Chem, 2005, 51: 898 - 900. (Received 2005210212) ( Edited by ZHAO Bo) ·101·Yong QU 溶酶体贮积病 溶酶体贮积病 Yong QU (Department of Genetic Testing, Kaiser Permanente, Southern California, 4580 Electronics Place, Los Angeles, CA 90039, USA) [关键词 ] 溶酶体贮积病 ;粘多糖累积病 ;寡糖贮积病 ; 粘脂质累积病 ;鞘脂类代谢障碍 [中图分类号 ] R589  [文献标识码 ] A  [文章编号 ] 16712167X (2006) 0120100203 《北京大学学报 (医学版 ) 》第八届编辑委员会第一次会议纪要   《北京大学学报 (医学版 ) 》(以下简称《学报 》)第八届编辑委员会第一次全体会议于 2005年 12月 22日在北京大学医学 部图书馆 408会议室召开。《学报 》第八届编辑委员会主编、全国人大常委会副委员长、北京大学医学部主任韩启德院士 ,《学 报 》常务副主编、北京大学常务副校长、医学部常务副主任柯杨教授出席了本次会议。会议由《学报 》副主编、北京大学医学部 副主任方伟岗教授主持。《学报 》编委、各二级单位科研部门代表及《学报 》编辑部全体成员出席了会议。 柯杨教授首先对学报近几年的工作给予了充分的肯定。她指出 :《学报 》始终坚持“学术至上 ,质量第一 ”的原则 ,是国内 同类高等学校医学学报中的品牌 ,具有北医特色。《学报 》的成就与两个因素密切相关 :一个是编辑部全体工作人员的团结协 作 ,另一个是各届编委、学术骨干的无私支持。 《学报 》副主编、编辑部主任周传敬编审代表《学报 》第七届编辑委员会汇报工作。5年来共召开编委定稿会 37次 ;出版 学报正刊 30期 ,增刊 2期 ,共 32期 ,包括《九十年校庆专刊 》、《SARS防治研究专刊 》和其他重点号 18期。《学报 》2001年 12 月入选新闻出版总署“中国期刊方阵 ”“双百期刊 ”层面 , 2003年被美国医学文献分析和联机检索系统 (MEDL INE)及其《医学 索引 》( IM )收录 , 2004年和 2005年连续入选“第三届中国百种杰出学术期刊 ”和“第四届中国百种杰出学术期刊 ”名单 ,入选 2004年中国科技期刊 CSCD (中国科学引文数据库 ,中国科学院文献情报中心 )影响因子 300名排行表 , 2004年入选《中文核 心期刊要目总览 (第 4版 ) 》综合性医药卫生类核心期刊 ,并荣获教育部优秀科技期刊一等奖。根据《中国科技期刊引证报告 (中国科学技术信息研究所 ) 》公布的数据 ,《学报 》影响因子由 2001年 0. 295升至 2004年 0. 634,总被引频次由 2001年 463 次 (他引率 0. 93)升至 2004年 739次 (他引率 0. 97)。 与会编委就《学报 》是否办成 Open Access (OA )期刊 ,是否改成英文版 ,以及《学报 》的功能定位等问题展开了热烈的讨 论。 1.关于《学报 》是否办成 Open Access(OA)期刊的问题 :方伟岗教授指出 , OA是一种很好的形式 ,发展前景很好。马大龙 教授谈到 ,办 OA期刊有很大的意义 ,很多科研文章的背后有大量的数据支持 ,由于不存在版面的限制 ,可以将这些信息放到 网络上 ,供读者参考、分析。但 OA同样存在一些问题 ,例如因审稿程序不严谨而可能降低数据的可信度 ;国内外各个杂志的 格式不统一 ,给交叉检索造成一定的困难。贾弘禔教授说 ,随着网络的发展 ,期刊的出版也会有大的变革 , 目前的纸质出版物 很可能有一部分会被淘汰 ,因此一定要搞电子版刊物 ,要扩大影响。韩济生院士、林志彬教授、黎晓新教授等也都认为 ,《学 报 》在网上开放是必要的。 2. 关于《学报 》是否改成英文版 :编委们认为 ,改英文版问题应该慎重 ,以免影响国内读者阅读和引用 ,目前可以根据情况 登一部分英文稿。林志彬教授、丁洁教授等提出 ,《学报 》论文的英文摘要应该更详细些 ,提供主要数据。 3.关于《学报 》的功能定位问题 :韩启德院士谈到 ,大学办学报的模式是经济的产物。《学报 》作为北京大学医学部自 己的刊物 ,应成为学术园地 ,可以以新闻的形式公布医学部的科研成果 ,研讨大家所关心的学术问题 ,而不仅仅是发表学术论 文。办刊思路上如果能突破 ,会将刊物办得非常活泼 ,读者不只看到学术文章 ,还可以看到国外其他相应工作的有关情况 ,以 及其他丰富的学术信息。柯杨教授谈到 ,学报的定位问题一直存在困惑。目前《学报 》在国内刊物中是质量较好的 ,但是否要 前瞻性地看一下 ,考虑 5年以后会是什么样。《学报 》可以增加一些趣味性的、评论性的内容 ,可以发表研究人员撰写的科研综 述 ,这是教科书里没有的内容 ,既能供读者参考借鉴 ,又可以减少其他相关研究人员的工作量 ,使大家都受益。《学报 》如此改 革 ,可能需要相应萎缩一部分内容 ,而同时又拓展另一部分内容。韩济生院士、王夔院士、唐朝枢教授、贾弘禔教授、林三仁教 授、陈贵安教授、姚晨教授和李凯教授分别就《学报 》办刊模式、栏目设置问题、国际合作问题、统计学审稿中的问题等发了言。 韩启德主编对会议进行了。他说 ,今后《学报 》的定位仍然是学术刊物 ,围绕着学术进行 ,但是不要在乎被 SC I收录、 影响因子、国内排名等 ,不要在乎《学报 》是否走向国际 ,要把《学报 》办成全面反映北医学术面貌、提供丰富学术信息的北医全 体师生的园地 ,以学报为名的一份学术杂志。可以借鉴 N ature, Science的形式。《学报 》的栏目可以逐步改成 :述评、评论性文 章 (一些新的思路、尖锐的观点 )、科研新闻、综述 (反映某个有重大进展的领域 )、科研论文 (有大篇幅的 ,也有短的 )、学科交 叉 (包括临床与基础的交叉 )、学者访谈、新书介绍等等。在栏目设置上 ,可以成熟一个发展一个 ,不必一步到位。网络版的问 题要作为专题来研究 ,网络版的内容可以更灵活一些。 ·201· 北 京 大 学 学 报 ( 医 学 版 ) JOURNAL OF PEKING UN IVERSITY(HEALTH SC IENCES)  Vol. 38 No. 1 Feb. 2006
/
本文档为【溶酶体贮积病_英文_】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑, 图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。 本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。 网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。

历史搜索

    清空历史搜索